Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 206

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Bayesian adaptive design for targeted therapy development in lung cancer — a step toward personalized medicine

Open access
Xian Zhou, Suyu Liu, Kim, Edward S, Herbst, Roy S, Lee, J Jack·2008·Clinical Trials

Abstract

Background: With the advancement in biomedicine, many biologically targeted therapies have been developed. These targeted agents, however, may not work for everyone. Biomarker profiles can be used to identify effective targeted therapies. Our goals are to characterize the molecular signature of individual tumors, offer the best-fit targeted therapies to patients in a study, and identify promising agents for future development. Methods: We propose an outcome-based adaptive randomization trial design for patients with advanced stage non-small cell lung cancer. All patients have baseline biopsy samples taken for biomarker assessment prior to randomization to treatments. The primary endpoint of this study is the disease control rate at 8 weeks after randomization. The Bayesian probit model is used to characterize the disease control rate. Patients are adaptively randomized to one of four treatments with the randomization rate based on the updated disease control rate from the accumulated data in the trial. For each biomarker profile, high-performing treatments have higher randomization rates, and vice versa. An early stopping rule is implemented to suspend low-performing treatments from randomization. Results: Based on extensive simulation studies, with a total of 200 evaluable patients, our trial has desirable operating characteristics to: (1) identify effective agents with a high probability; (2) suspend ineffective agents; and (3) treat more patients with effective agents that correspond to their biomarker profiles. Our trial design continues to update and refine the estimates as the trial progresses. Limitations: This biomarker-based trial requires biopsible tumors and a two-week turn around time for biomarker profiling before randomization. Additionally, in order to learn from the interim data and adjust the randomization rate accordingly, the outcome-based adaptive randomization design is applicable only for trials when the endpoint can be assessed in a relative short period of time. Conclusion: Bayesian adaptive randomization trial design is a smart, novel, and ethical design. In conjunction with an early stopping rule, it can be used to efficiently identify effective agents, eliminate ineffective ones, and match effective treatments with patients' biomarker profiles. The proposed design is suitable for the development of targeted therapies and provides a rational design for personalized medicine. Clinical Trials 2008; 5: 181—193. http://ctj.sagepub.com

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/1740774508091815

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 206

Metadata

Authors
Zhou, X., Liu, S., Kim, E. S., Herbst, R. S., & Lee, J. J.
Venue
Clinical Trials
Published
2008-06
Volume
5
Issue
3
Pages
181-193
ISSN
  • 1740-7745 (ISSN-L)
  • 1740-7753
OpenAlex
W2155291829
Cited by
206
References
1
FWCI
11.18
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bayesian adaptive design for targeted therapy development in lung cancer — a step toward personalized medicine. https://app.cochat.ai/papers/10.1177/1740774508091815
The paper
Zhou, X., Liu, S., Kim, E. S., Herbst, R. S., & Lee, J. J. (2008). Bayesian adaptive design for targeted therapy development in lung cancer — a step toward personalized medicine. Clinical Trials. https://doi.org/10.1177/1740774508091815

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.